Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Publisher： Karger

E-ISSN： 1421-9832|225|4|326-332

ISSN： 1018-8665

Source： Dermatology, Vol.225, Iss.4, 2013-01, pp. : 326-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice

By  

Dermatology, Vol. 220, Iss. 2, 2010-02 ,pp. : 128-137

Karger

Access to resources Recommend Favorite

Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis

By  

Dermatology, Vol. 223, Iss. 1, 2011-08 ,pp. : 80-86

Karger

Access to resources Recommend Favorite

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

By  

Dermatology, Vol. 219, Iss. 3, 2009-09 ,pp. : 239-249

Karger

Access to resources Recommend Favorite

Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent

By  

Dermatology, Vol. 230, Iss. 4, 2015-02 ,pp. : 347-353

Karger

Access to resources Recommend Favorite

Patient-Reported Outcome Measurement in Clinical Dermatological Practice: Relevance and Feasibility of a Web-Based Portal

By  

Dermatology, Vol. 232, Iss. 1, 2016-0 ,pp. : 64-70

Karger

Access to resources Recommend Favorite